Tvardi Therapeutics racks up $74m Series B

Tvardi Therapeutics Inc, a biopharmaceutical company, has secured $74 million in Series B financing.

Tvardi Therapeutics Inc, a biopharmaceutical company, has secured $74 million in Series B financing. Slate Path Capital, Palkon Capital, ArrowMark Partners, and 683 Capital led the round.

Source: Press Release